Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1992 1
1997 2
1998 1
2000 3
2002 2
2003 2
2004 3
2005 5
2006 3
2008 5
2009 1
2010 3
2011 4
2012 7
2013 12
2014 6
2015 5
2016 10
2017 17
2018 7
2019 9
2020 13
2021 11
2022 20
2023 21
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Results by year

Filters applied: . Clear all
Page 1
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, Joshua AM, Sacco JJ, Shoushtari AN, Orloff M, Piulats JM, Milhem M, Salama AKS, Curti B, Demidov L, Gastaud L, Mauch C, Yushak M, Carvajal RD, Hamid O, Abdullah SE, Holland C, Goodall H, Piperno-Neumann S; IMCgp100-202 Investigators. Nathan P, et al. N Engl J Med. 2021 Sep 23;385(13):1196-1206. doi: 10.1056/NEJMoa2103485. N Engl J Med. 2021. PMID: 34551229 Free article. Clinical Trial.
BACKGROUND: Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma. Data showing a proven overall survival benefit …
BACKGROUND: Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall su …
Metastatic uveal melanoma: The final frontier.
Rantala ES, Hernberg MM, Piperno-Neumann S, Grossniklaus HE, Kivelä TT. Rantala ES, et al. Prog Retin Eye Res. 2022 Sep;90:101041. doi: 10.1016/j.preteyeres.2022.101041. Epub 2022 Jan 6. Prog Retin Eye Res. 2022. PMID: 34999237 Free article. Review.
The final frontier in conquering uveal melanoma lies in solving these issues to cure metastatic disease. Most studies on metastatic uveal melanoma are small, uncontrolled, retrospective, and do not report staging. ...Promoting dormancy of micrometastases, har …
The final frontier in conquering uveal melanoma lies in solving these issues to cure metastatic disease. Most studies on metastatic …
T-cell-engaging bispecific antibodies in cancer.
van de Donk NWCJ, Zweegman S. van de Donk NWCJ, et al. Lancet. 2023 Jul 8;402(10396):142-158. doi: 10.1016/S0140-6736(23)00521-4. Epub 2023 Jun 1. Lancet. 2023. PMID: 37271153 Review.
Nevertheless, BsAb-mediated recognition of a peptide fragment of gp100 presented by HLA-A2:01 molecules has shown marked activity in patients with unresectable or metastatic uveal melanoma. Cytokine release syndrome is the most frequent toxicity associated wi …
Nevertheless, BsAb-mediated recognition of a peptide fragment of gp100 presented by HLA-A2:01 molecules has shown marked activity in patient …
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, Schlaak M, Butler MO, Sullivan RJ, Dummer R, Kirkwood JM, Orloff M, Sacco JJ, Ochsenreither S, Joshua AM, Gastaud L, Curti B, Piulats JM, Salama AKS, Shoushtari AN, Demidov L, Milhem M, Chmielowski B, Kim KB, Carvajal RD, Hamid O, Collins L, Ranade K, Holland C, Pfeiffer C, Nathan P. Hassel JC, et al. N Engl J Med. 2023 Dec 14;389(24):2256-2266. doi: 10.1056/NEJMoa2304753. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870955 Clinical Trial.
BACKGROUND: Tebentafusp, a T-cell receptor-bispecific molecule that targets glycoprotein 100 and CD3, is approved for adult patients who are positive for HLA-A*02:01 and have unresectable or metastatic uveal melanoma. The primary analysis in the present phase …
BACKGROUND: Tebentafusp, a T-cell receptor-bispecific molecule that targets glycoprotein 100 and CD3, is approved for adult patients who are …
Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Chen LN, Carvajal RD. Chen LN, et al. Expert Rev Anticancer Ther. 2022 Oct;22(10):1017-1027. doi: 10.1080/14737140.2022.2124971. Epub 2022 Sep 19. Expert Rev Anticancer Ther. 2022. PMID: 36102132 Free PMC article. Review.
INTRODUCTION: Metastatic uveal melanoma is associated with poor prognosis and few treatment options. ...EXPERT OPINION: Tebentafusp has transformed the treatment paradigm for metastatic uveal melanoma and should be the preferred frontline …
INTRODUCTION: Metastatic uveal melanoma is associated with poor prognosis and few treatment options. ...EXPERT OPINION: …
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
Middleton MR, McAlpine C, Woodcock VK, Corrie P, Infante JR, Steven NM, Evans TRJ, Anthoney A, Shoushtari AN, Hamid O, Gupta A, Vardeu A, Leach E, Naidoo R, Stanhope S, Lewis S, Hurst J, O'Kelly I, Sznol M. Middleton MR, et al. Clin Cancer Res. 2020 Nov 15;26(22):5869-5878. doi: 10.1158/1078-0432.CCR-20-1247. Epub 2020 Aug 18. Clin Cancer Res. 2020. PMID: 32816891 Free PMC article. Clinical Trial.
PURPOSE: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain, which redirects T cells to kill gp100-expressing tumor …
PURPOSE: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a melanoma-associated antigen) through a high a …
Tebentafusp: First Approval.
Dhillon S. Dhillon S. Drugs. 2022 Apr;82(6):703-710. doi: 10.1007/s40265-022-01704-4. Drugs. 2022. PMID: 35364798 Review.
Tebentafusp is under regulatory review for the treatment of metastatic uveal melanoma in the UK, Australia and Canada. Clinical studies of tebentafusp are underway for uveal melanoma and cutaneous melanoma in several countries worldwide. This article s …
Tebentafusp is under regulatory review for the treatment of metastatic uveal melanoma in the UK, Australia and Canada. …
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.
Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi A, Hernandez-Aya L, Nathan P, Hamid O, Piulats JM, Rioth M, Johnson DB, Luke JJ, Espinosa E, Leyvraz S, Collins L, Goodall HM, Ranade K, Holland C, Abdullah SE, Sacco JJ, Sato T. Carvajal RD, et al. Nat Med. 2022 Nov;28(11):2364-2373. doi: 10.1038/s41591-022-02015-7. Epub 2022 Oct 13. Nat Med. 2022. PMID: 36229663 Free PMC article. Clinical Trial.
In patients with previously treated metastatic uveal melanoma, the historical 1 year overall survival rate is 37% with a median overall survival of 7.8 months. ...In an exploratory analysis, early on-treatment reduction in circulating tumour DNA was strongly …
In patients with previously treated metastatic uveal melanoma, the historical 1 year overall survival rate is 37% with …
Uveal melanoma.
Spagnolo F, Caltabiano G, Queirolo P. Spagnolo F, et al. Cancer Treat Rev. 2012 Aug;38(5):549-53. doi: 10.1016/j.ctrv.2012.01.002. Epub 2012 Jan 24. Cancer Treat Rev. 2012. PMID: 22270078 Review.
Up to 50% of patients with primary uveal melanoma will ultimately develop distant metastasis, the liver being involved in up to 90% of individuals and the median survival reported to be 4-5 months. The current treatment of metastatic uveal melanoma is limited …
Up to 50% of patients with primary uveal melanoma will ultimately develop distant metastasis, the liver being involved in up to 90% of indiv …
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.
Carvajal RD, Nathan P, Sacco JJ, Orloff M, Hernandez-Aya LF, Yang J, Luke JJ, Butler MO, Stanhope S, Collins L, McAlpine C, Holland C, Abdullah SE, Sato T. Carvajal RD, et al. J Clin Oncol. 2022 Jun 10;40(17):1939-1948. doi: 10.1200/JCO.21.01805. Epub 2022 Mar 7. J Clin Oncol. 2022. PMID: 35254876 Free PMC article. Clinical Trial.
PURPOSE: This phase I study aimed to define the recommended phase II dose (RP2D) of tebentafusp, a first-in-class T-cell receptor/anti-CD3 bispecific protein, using a three-week step-up dosing regimen, and to assess its safety, pharmacokinetics, pharmacodynamics, and preliminary …
PURPOSE: This phase I study aimed to define the recommended phase II dose (RP2D) of tebentafusp, a first-in-class T-cell receptor/anti-CD3 b …
165 results